Abstract: Automated and dynamic client and product/account onboarding assembly line for a firm dynamically configures a product/account type in any business line from any user/application channel of the firm. The client and product/account onboarding assembly line comprises changeable framework that dynamically configures each step according to the particular requirements of the product/account of the client. The assembly line can comprise two dynamic stages that together build any product/account type and test beds that automatically detect and discard any incorrectly assembled outputs.

Abstract: Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT/E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

Abstract: Present invention relates to a method of making a recombinant p80 polypeptide using an E. coli culture comprising a plurality of E. coli host cells each transformed or transfected with an expression vector containing a DNA fragment encoding a recombinant p80 polypeptide; and inducing the E. coli culture by adding a 0.2% L-Arabinose. The isolated, recombinant p80 is added to a pharmaceutical composition, wherein it binds to a therapeutic agent comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. The p80 polypeptide enhances the transportation of the therapeutic agent into the bloodstream by the p80 functioning as a tight junction modulator to enhance the permeability of the intestinal epithelium to the therapeutic agent.

Abstract: Some disclosed methods involve performing a fingerprint enrollment process involving obtaining fingerprint image data via a first fingerprint sensor of a fingerprint sensor system including two or more fingerprint sensors and creating a first fingerprint sensor template for subsequent fingerprint authentication via the first fingerprint sensor. Some disclosed methods involve determining a second fingerprint sensor of the fingerprint sensor system for which a fingerprint template will be created, determining one or more second fingerprint sensor characteristics of the second fingerprint sensor and creating a second fingerprint sensor template for subsequent fingerprint authentication via the second fingerprint sensor based, at least in part, on the first fingerprint sensor template and the one or more second fingerprint sensor characteristics.

Abstract: Present invention relates to a pharmaceutical composition comprising P80 with drugs, dyes, small molecules, biomolecules, proteins or combination thereof. P80 enhances the transportation of molecules associated with it. The P80 is a tight junction modulators to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery. The invention further provides a process for the preparation, isolation and purification of p80 protein.

Abstract: Described are systems and methods for in-facility purchase of items from a single seller when those items are offered for sale by multiple sellers. For example, a materials handling facility may include two or more sellers (Seller A and Seller B) that offer items for sale within the facility. A user may pick items from Seller A and items from Seller B and complete an in-facility purchase of those picked items from one of the sellers, such as Seller B, by payment of the purchase price and applicable taxes to that seller. At a subsequent time, for example when the user exits the facility, Seller B may pay Seller A at least a portion of the purchase price for the Seller A items sold by Seller B as part of the in-facility purchase.

Abstract: A static transfer switch (STS) system for transferring power between power sources is provided. The STS system includes first and second alternate-current (AC) switch assemblies. The first AC switch assembly includes a first current interrupter, and a first controller configured to control the first current interrupter. The second AC switch assembly includes a second current interrupter, and a second controller configured to control the second current interrupter. The first AC switch assembly and the second AC switch assembly are in communication with one another and are each configured to monitor an output power to the load, the first power source, and the second power source and transfer power when disturbance is detected in the output power, the first power source, and/or the second power source.

Abstract: A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

Abstract: Methods of making the M or L complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), and methods of using to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.

Abstract: The present invention is directed to a composition, mammalian cell and vector, and a method for the production of, and method of treatment with, a recombinant protein vaccine in a mammalian cell line. The methods and compositions are particularly useful for generating the stable expression of a recombinant protein vaccine of interest. The invention is particularly useful for the production of vaccines to aid in protection against viral pathogens for vertebrates, in particular mammalians, especially humans. The mammalian cell for producing a protein of interest comprises: a plasmid encoded with a nucleotide sequence encoding one or more epitopes or subunits of the SARS-CoV-2 that are embedded in the nucleotide sequence encoding a detoxified recombinant tetanus toxin (DrTeNT).

Abstract: In some aspects, an electronic device may display a keyboard user interface on a touchscreen display panel. The electronic device may detect a key press interaction with the keyboard user interface. The electronic device may trigger one or more haptic actuators to generate a vibration waveform associated with a haptic pattern that is based at least in part on a context associated with the key press interaction. Numerous other aspects are described.

Abstract: A magnetoresistive random-access memory (MRAM) device includes a magnetoresistive tunnel junction (MTJ) device, an electrode, and a coupling layer. The MTJ device includes a free layer, a fixed layer, and a tunnel barrier layer positioned between the free layer and the fixed layer. The coupling layer is positioned between and coupling the electrode and the MTJ device. The coupling layer includes spin Hall channel (SHC) material. The free layer, the fixed layer, and the tunnel barrier layer are stacked in a first direction to form MTJ device. The electrode is nonaligned with the MTJ device such that the electrode is spaced away from the MTJ in a second direction that is different from the first direction.

Abstract: Some disclosed methods involve performing a fingerprint enrollment process involving obtaining fingerprint image data via a first fingerprint sensor of a fingerprint sensor system including two or more fingerprint sensors and creating a first fingerprint sensor template for subsequent fingerprint authentication via the first fingerprint sensor. Some disclosed methods involve determining a second fingerprint sensor of the fingerprint sensor system for which a fingerprint template will be created, determining one or more second fingerprint sensor characteristics of the second fingerprint sensor and creating a second fingerprint sensor template for subsequent fingerprint authentication via the second fingerprint sensor based, at least in part, on the first fingerprint sensor template and the one or more second fingerprint sensor characteristics.

Abstract: Some methods may involve receiving fingerprint image data and a first set of background image data from a fingerprint sensor and determining first processed fingerprint image data via a subtraction of the first set of background image data from the fingerprint image data. Some methods may involve obtaining force data corresponding to a force applied to the fingerprint sensor when the fingerprint image data were obtained. Some methods may involve obtaining a second set of background image data corresponding to the force data. Some methods may involve determining second processed fingerprint image data based, at least in part, on the first processed fingerprint image data and the second set of background image data, and outputting the second processed fingerprint image data. In some examples, determining the second processed fingerprint image data may involve a machine learning model. Some examples may involve estimating residual noise based on the force data.

Abstract: A pharmaceutical composition, method of making and treating, comprising one or more proteins of Clostridium botulinum in a nano-emulsion for topical delivery to treat primarily skin disorders. In an embodiment, the nano-emuslisons are encapsulated microspheres and nanospheres comprising: propylene glycol, phenoxyethanol, sodium hyaluronate, caprylic/capric triglyceride, hydrogenated castor oil, span-80, and saponin, with water. A method of making the nanoemulsions, comprises: (1) preparing a solution A by mixing sodium hyaluronate, propylene glycol, Tween-80 and saponin in water by continuous stirring; (2) preparing a solution B by mixing phenoxy ethanol and carylic acid, or capric triglyceride, together; (3) mixing B into A by continuous stirring for 15 minutes to form solution C; (4) mixing Botulinum toxin and 10 mM Sodium Phosphate buffer to a pH of 7.1, and adding to solution C; and (5) stirring solution C at room temperature for 15-20 minutes.

Abstract: A recombinant SARS-CoV2 protein-based vaccine, and method of immunizing, is developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, such as a detoxified recombinant tetanus neurotoxin (DrTeNT), to develop a novel vaccine to immunize against SARS-CoV2. The developed vaccine will have three novel contributions compared to the present vaccine technology; a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is to be used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

Abstract: The present invention comprises of a vaccine technology to produce one or more novel vaccine compositions, method of making, and administering, for protecting against at least two of the four serotypes of the dengue virus. The vaccine technology is based on four important ideas: a) using a backbone for a vaccine candidate comprising detoxified tetanus neurotoxin—DrTeNT; b) selecting epitopes that can activate both B-cells and T-cells in a patient to whom the vaccine is administered to provide long term immunity; c) immunizing against all the four serotypes of dengue; and d) an oral/sublingual/buccal/nasal delivery platform and formulation.

Abstract: Compositions and methods are described for oral treatment of gastric cancer. A composition of matter for treatment of gastric cancer includes navitoclax; and Bcl2 siRNA. The composition can include ?-glucan and docosahexaenoic acid as a mucoadhesive nanocarrier.

Abstract: Compositions and methods are described for oral treatment of stomach cancer. A composition of matter for treatment of stomach cancer includes fluoreuracil-5; and Bcl2 siRNA. The composition can include ?-glucan as a mucoadhesive nanocarrier.

Abstract: A computer remediates data quality issues in a consolidated data record includes elements from several datasets, comprising. The computer determines, based at least in part on dataset feed information, dataset flow quality value for first and second datasets for a consolidated data record resulting from combining a plurality of datasets. The datasets include associated metadata. The computer, responsive to flow quality value determinations, compares dataset flow quality values with a predetermined dataset flow quality threshold and conducts a correction action for datasets with dataset flow quality value beyond the threshold. The computer determines, based at least in part on said dataset element health information, dataset health quality values for the datasets.